+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases



Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases



Journal of the National Cancer Institute 106(7):



Median survival of non-small cell lung cancer (NSCLC) patients with brain metastases is poor. We examined concurrent erlotinib and whole brain radiotherapy (WBRT) followed by maintenance erlotinib in patients with untreated brain metastases, given the potential radiosensitizing properties of erlotinib and its direct effect on brain metastases and systemic activity. Eighty NSCLC patients with KPS of 70 and greater and multiple brain metastases were randomly assigned to placebo (n = 40) or erlotinib (100mg, n = 40) given concurrently with WBRT (20 Gy in 5 fractions). Following WBRT, patients continued with placebo or erlotinib (150 mg) until disease progression. The primary end point was neurological progression-free survival (nPFS); hazard ratios (HRs) were calculated using Cox regression. All P values were two-sided. Fifteen patients (37.5%) from each arm were alive and without neurological progression 2 months after WBRT. Median nPFS was 1.6 months in both arms; nPFS HR 0.95 (95% CI = 0.59 to 1.54; P = .84). Median overall survival (OS) was 2.9 and 3.4 months in the placebo and erlotinib arms; HR 0.95 (95% CI = 0.58 to 1.55; P = .83). The frequency of epidermal growth factor receptor (EGFR) mutations was low with only 1 of 35 (2.9%) patients with available samples had activating EGFR-mutations. Grade 3/4 adverse event rates were similar between the two groups (70.0% in each arm), except for rash 20.0% (erlotinib) vs 5.0% (placebo), and fatigue 17.5% vs 35.0%. No statistically significant quality of life differences were found. Our study showed no advantage in nPFS or OS for concurrent erlotinib and WBRT followed by maintenance erlotinib in patients with predominantly EGFR wild-type NSCLC and multiple brain metastases compared to placebo. Future studies should focus on the role of erlotinib with or without WBRT in patients with EGFR mutations.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055358916

Download citation: RISBibTeXText

PMID: 25031274

DOI: 10.1093/jnci/dju151


Related references

Ma08.01 Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus Wbrt Alone for Nsclc with Brain Metastases (Enter). Journal of Thoracic Oncology 13(10): S381-S382, 2018

A Clinical Observation of Concomitant Therapy of Erlotinib and Whole Brain Radiotherapy in Patients of NSCLC Combined with Brain Metastases.. Zhongguo Fei Ai Za Zhi 12(12): 1291-1294, 2009

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma. Drug Design Development and Therapy 7: 1179-1186, 2013

Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. International Journal of Radiation Oncology Biology Physics 74(5): 1391-1396, 2009

Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. International Journal of Radiation Oncology, Biology, Physics 61(1): 185-191, 2005

Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?. Journal of Clinical Oncology 31(25): 3164-3165, 2013

From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC. Journal of Oncology 2019: 3267409, 2019

Evaluation of Stereotactic Radiotherapy of the Resection Cavity After Surgery of Brain Metastases Compared to Postoperative Whole-Brain Radiotherapy (ESTRON)-A Single-Center Prospective Randomized Trial. Neurosurgery 83(3): 566-573, 2018

Analysis of prognostic factors in NSCLC patients with brain metastases 
diagnosed by constrast-enhanced MRI after whole brain radiotherapy. Zhongguo Fei Ai Za Zhi 14(9): 719-722, 2011

Whole brain radiotherapy in patients with NSCLC and brain metastases. Lancet 388(10055): 1960-1962, 2016

Erlotinib plus concurrent whole-brain radiation therapy for non-small cell lung cancers patients with multiple brain metastases. Translational Lung Cancer Research 5(2): 208-211, 2016

Phase II with Taxol (Paclitaxel) (T), Carboplatin (C) and brain radiotherapy (RT) in patients (PTS) with inoperable brain metastases (BM) of non-small cell lung cancer (NSCLC). Lung Cancer 29(1): 259-260, 2000

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. Journal of Clinical Oncology 31(7): 895-902, 2013

Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118. International Journal of Radiation Oncology Biology Physics 71(1): 71-78, 2008

Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial. JAMA Oncology 1(4): 457-464, 2015